Cas:1187385-86-9 6-Fluoro-1-methyl-1H-benzo[d]imidazole manufacturer & supplier

We serve Chemical Name:6-Fluoro-1-methyl-1H-benzo[d]imidazole CAS:1187385-86-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

6-Fluoro-1-methyl-1H-benzo[d]imidazole

Chemical Name:6-Fluoro-1-methyl-1H-benzo[d]imidazole
CAS.NO:1187385-86-9
Synonyms:6-fluoro-1-methylbenzimidazole;6-Fluoro-1-methylbenzoimidazole
Molecular Formula:C8H7FN2
Molecular Weight:150.15300
HS Code:2933990090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:17.82000
Exact Mass:150.05900
LogP:1.71240

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 6-fluoro-1-methylbenzimidazole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-Fluoro-1-methylbenzoimidazole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-fluoro-1-methylbenzimidazole Use and application,6-Fluoro-1-methylbenzoimidazole technical grade,usp/ep/jp grade.


Related News: MSD – known as Merck in the US and Canada – is jointly developing Verquvo with Bayer. While MSD hold the commercial rights to the heart failure med in the US, Bayer has the exclusive commercial rights in the rest of the world. (3S,4S)-4-amino-N-((S)-1-(((S)-1-((2-amino-2-oxoethyl)amino)-4-methyl-1-oxopentan-2-yl)amino)-1-oxopropan-2-yl)-3-hydroxy-6-methyl-N-((3-methylbutanoyl)-L-valyl-L-leucyl)heptanamide manufacturers The collaborative research and exclusive license agreement inked in December didn’t have a price tag, but the two companies revealed the eye-popping figure Tuesday that includes an undisclosed upfront payment to PeptiDream and other cash drops subject to certain clinical milestones. 9a-Hydroxymethyl-1,2,3,4,5,6,9,9a-octahydro-benzocyclohepten-4a-ol suppliers The CHMP has agreed on an update of recommendations for monitoring patients. Healthcare professionals should now check their patients for signs of blood cancers at least once a year for 15 years.1 2-(acetoxymethyl)-4-(3,4-methylenedioxyphenyl)-1-butene vendor & factory.